MARKET NEWS

Pfanstiehl Launches New cGMP-Produced, Parenteral-Grade Arginine for Biopharmaceutical & Pharmaceutical Formulations
Dalton Pharma Services Invests in Fully Automated Sterile Liquid Filling System
Telix Completes Acquisition of Atlab for Prostate Cancer Program
IMV Announces Phase 2 Basket Trial in Collaboration With Merck
SAMDI Tech Increases Clients’ Opportunities for Drug Candidate Hit Finding With Charles River Partnership
PCI Pharma Services Announces Agreement to Acquire Sherpa Clinical Packaging

  FEATURED EDITORIAL

  COMPANY PROFILE

At SGW Pharma Marketing, we never lose sight that branding a technology or service is more engaging when you make a real connection with people. Our formula blends the “human factor” into each of our brand-building strategies. Whether you’re talking to R&D scientists, business development professionals, or C-level executives, we focus on creating tailored messaging to each group and delivering it via a wide range of services. With 27 years of consumer and B2B pharma experience, you can count on us to deliver innovative solutions that make a difference. That’s why the top pharmaceutical companies choose SGW Pharma. Contact Amy Bunn at abunn@sgw.com or (973) 585-1264. Click here for more.

  EXCLUSIVE ONLINE CONTENT

VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate

VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate

VistaGen Therapeutics, Inc. and Pherin Pharmaceuticals, Inc. recently announced the signing of a license agreement granting VistaGen exclusive worldwide rights to develop and commercialize PH94B nasal spray, a Phase 3-ready drug candidate for as-needed (PRN) treatment of Social Anxiety Disorder (SAD).

PAREXEL Advances Patient-Centric Drug Development With Introduction of its Patient Innovation Center

PAREXEL Advances Patient-Centric Drug Development With Introduction of its Patient Innovation Center

PAREXEL International Corporation, a leading innovator of global biopharmaceutical services, today announced the launch of its Patient Innovation Center, designed to help guide sponsors in their efforts to improve efficiency and success across all areas of biopharmaceutical development including clinical trial design, recruitment, execution and market access. 

Biothera Pharmaceuticals Announces Immuno-Oncology Clinical Trial Collaboration With AstraZeneca

Biothera Pharmaceuticals Announces Immuno-Oncology Clinical Trial Collaboration With AstraZeneca

Biothera Pharmaceuticals, Inc. recently announced a clinical collaboration with AstraZeneca to evaluate whether the combination of Biothera’s Imprime PGG and AstraZeneca’s durvalumab (IMFINZI) can decrease tumor volume in patients with primary untreated locally advanced head and neck cancer prior to surgical resection.

Metrion Biosciences & AMRI Collaborate to Offer Ion Channel Drug Discovery Services

Metrion Biosciences & AMRI Collaborate to Offer Ion Channel Drug Discovery Services

Metrion Biosciences Limited and AMRI recently announced they have signed a new collaboration agreement. The alliance will promote Metrion’s electrophysiology and ion channel screening expertise to global pharmaceutical and biotechnology clients.

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

September 26 – Excipients

October 3 – Gene Therapy